Innate Pharma S.A. (IPHA)

2,5454 +0,0954 (+3,89%) Alla chiusura: 04:00PM EDT

Innate Pharma S.A.

117, Avenue de Luminy
BP 30191
Marseille 13009
France
33 4 30 30 30 30
https://www.innate-pharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 179

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Herve Brailly Ph.D.	Co-Founder, Interim CEO & Chairman of Executive Board	N/D	N/D	1961
Mr. Yannis Morel Ph.D.	Executive VP, COO & Member of Executive Board	386,18k	N/D	1973
Dr. François Romagné Ph.D.	Founder	N/D	N/D	1964
Mr. Eric Vivier D.V.M., M.B.A., Ph.D.	Founder, Senior VP & Chief Scientific Officer	N/D	N/D	1964
Dr. Marc Bonneville Ph.D.	Founder	N/D	N/D	1960
Mr. Jean Jacques Fournié Ph.D.	Founder	N/D	N/D	N/D
Mr. Alessandro Moretta M.D., Ph.D.	Founder	N/D	N/D	N/D
Mr. Frederic Lombard M.B.A.	Senior VP & CFO	N/D	N/D	1975
Dr. Sonia Quaratino M.D., Ph.D.	Executive VP, Chief Medical Officer & Member of Executive Board	N/D	N/D	1967
Mr. Arvind Sood	Executive VP, President of US Operations & Member of Executive Board	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Governance aziendale

L'ISS Governance QualityScore di Innate Pharma S.A. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.